Media headlines about Reata Pharmaceuticals (NASDAQ:RETA) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Reata Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.0042769934202 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
RETA has been the subject of several research reports. Cowen reissued a “buy” rating on shares of Reata Pharmaceuticals in a report on Thursday, December 14th. ValuEngine downgraded shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Zacks Investment Research downgraded shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, January 24th. BidaskClub downgraded shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, December 5th. Finally, Robert W. Baird reaffirmed a “buy” rating and issued a $47.00 price target on shares of Reata Pharmaceuticals in a report on Tuesday, October 24th. Three research analysts have rated the stock with a sell rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $54.71.
Reata Pharmaceuticals (RETA) traded down $0.64 during trading on Friday, reaching $26.22. 345,097 shares of the company were exchanged, compared to its average volume of 164,433. The company has a debt-to-equity ratio of -0.15, a current ratio of 3.18 and a quick ratio of 3.18. Reata Pharmaceuticals has a 12 month low of $19.48 and a 12 month high of $40.88. The stock has a market cap of $684.68, a price-to-earnings ratio of -17.14 and a beta of -2.52.
In other news, Director James Edward Bass bought 3,888 shares of the stock in a transaction on Wednesday, November 15th. The stock was bought at an average cost of $24.02 per share, for a total transaction of $93,389.76. Following the completion of the purchase, the director now directly owns 52,089 shares in the company, valued at $1,251,177.78. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Cpmg Inc bought 200,000 shares of the stock in a transaction on Thursday, December 14th. The stock was purchased at an average price of $24.79 per share, with a total value of $4,958,000.00. Following the completion of the purchase, the director now owns 113 shares of the company’s stock, valued at $2,801.27. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 413,813 shares of company stock valued at $10,453,354. 44.00% of the stock is owned by insiders.
WARNING: This story was originally published by Week Herald and is owned by of Week Herald. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://weekherald.com/2018/02/11/reata-pharmaceuticals-reta-receiving-somewhat-favorable-news-coverage-analysis-finds.html.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.